Pfizer to manufacture remdesivir for Gilead

By The Science Advisory Board staff writers

August 7, 2020 -- Pfizer has inked a multiyear agreement with Gilead Sciences to manufacture and supply Gilead's investigational antiviral drug remdesivir, joining other external manufacturing organizations in supporting efforts to scale up supply for the treatment of COVID-19.

Under the agreement, Pfizer will provide contract manufacturing services at its McPherson, KS, facility to manufacture and supply remdesivir for Gilead. This is part of the company's commitment to working with other pharmaceutical companies to address the COVID-19 crisis.

If you like this content, please share it with a colleague!

Related Reading

Pfizer, BioNTech get $1.95B for SARS-CoV-2 vaccine
Pfizer and BioNtech have inked an agreement with the U.S. Department of Health and Human Services and the Department of Defense, as part of the federal...

Pfizer, BioNTech release clinical data for COVID-19 vaccine candidate
Pfizer and BioNTech have released initial data from an ongoing phase I/II clinical trial for the COVID-19 messenger RNA-based vaccine candidate BNT162b1.

Pfizer pledges $100M for antimicrobial resistance
Pfizer has pledged $100 million to the Antimicrobial Resistance Action Fund to address the need for new antibiotics due to the rapid rise of antibiotic-resistant...

Gilead licenses remdesivir to increase global access
Gilead Sciences has inked several agreements for the manufacture and distribution of remdesivir, which has been issued an emergency use authorization...

FDA issues EUA for remdesivir to treat severe COVID-19 cases
The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for the investigational antiviral drug remdesivir to be used...

Controversy hits Gilead over orphan status for COVID-19 drug
Gilead Sciences has rescinded its request for orphan drug status for an experimental drug for treating COVID-19 just two days after getting approval from...